Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 223 results for myocardial infarction

  1. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  2. Guidance on the use of coronary artery stents (TA71)

    Evidence-based recommendations on using coronary artery stents in adults.

  3. NICE impact cardiovascular disease management

    Find out about the progress made by the health and care system in implementing NICE guidance on cardiovascular disease management

  4. Adoption of high-sensitivity cardiac troponin for early rule out of NSTEMI at Belfast Health and Social Care Trust

    1-hour protocol using high sensitivity troponin assay to assess acute myocardial infarction (AMI) in patients presenting with chest...

  5. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

  6. Research is recommended in the UK clinical setting to compare the BRAHMS copeptin assay in combination with cardiac troponin testing against sequential cardiac troponin testing for ruling out myocardial infarction.

    testing against sequential cardiac troponin testing for ruling out myocardial infarction. Any explanatory notes(if applicable) Research...

  7. Bioresorbable stent implantation to treat coronary artery disease (IPG732)

    Evidence-based recommendations on bioresorbable stent implantation to treat coronary artery disease in adults. This involves implanting a stent (small tube) into a narrowed artery to widen it.

  8. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

  9. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

  10. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

  11. MiraQ for assessing graft flow during coronary artery bypass graft surgery (MTG8)

    Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.

  12. Drug-eluting stents for the treatment of coronary artery disease (TA152)

    Evidence-based recommendations on using drug-eluting stents in adults.

  13. HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (MTG32)

    Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.

  14. Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)

    NICE has developed a medtech innovation briefing (MIB) on Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome .

  15. Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG494)

    Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting. This involves removing the vein under endoscopic guidance through a small cut near the knee (keyhole surgery).